A Research Study to See if Kidney Damage in People with Chronic Kidney Disease and Type 2 Diabetes Living with Overweight or Obesity Can Be Reduced by CagriSema Compared to Semaglutide Cagrilintide and Placebo
Brief description of study
The purpose of this study to see if CagriSema can lower kidney damage in people with with chronic kidney disease (CKD), type 2 diabetes (T2D), and overweight or obesity. We will also compare the effect of CagriSema to semaglutide and cagrilintide, when they are taken alone, and to placebo.
Type 2 diabetes is a disease where the blood sugar is not well controlled. This is because the body
does not react well to insulin and does not produce enough insulin.
Having T2D can cause many different health problems, for example CKD. If untreated, CKD is likely to
worsen over the years. Keeping a well-controlled blood sugar and body weight may reduce the risk of
getting the disease or worsening of the disease. Thus, apart from keeping a well-controlled blood sugar
and body weight, people with CKD also need treatment to prevent or lower the kidney damage and
keep their kidneys from getting worse.
CagriSema is an investigational drug that’s a combination of two other drugs: cagrilintide and
semaglutide.
- Cagrilintide is an investigational medicine under development.
- Semaglutide is FDA-approved to treat people with type 2 diabetes and overweight. Semaglutide is a medicine similar to a hormone called glucagon-like peptide-1 (GLP-1) that is made in your body after a meal. Semaglutide makes you feel full and less hungry and helps your body to regulate its blood sugar levels.
- Both medicines can lower blood sugar and body weight, and they may do so more when taken together than alone.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
